CliffBio
small molecule

CYCLOSPORINE

CYCLOSPORINE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameCYCLOSPORINE
Active ingredientCYCLOSPORINE
Strength100MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2000
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CYCLOSPORINE patent cliff — loss of exclusivity — | CliffBio